NCT00569127
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who have received prior interferon, bevacizumab, or any other therapy targeting VEGF or VEGF receptors; Patients with more than one prior regimen of cytotoxic chemotherapy; Patients with history of brain metastasis
https://ClinicalTrials.gov/show/NCT00569127